SCHEMBL4096488

SCHEMBL4096488

O=C(COc1ccc(Cl)cc1Cl)Nc1cccc(C(=O)Nc2ccccc2C(=O)O)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.64
KMT2A Q03164 5/20 0.64
ALDH1A1 P00352 3/20 0.64
KDM4E B2RXH2 1/20 0.64
CTDSP1 Q9GZU7 1/20 0.60
NOD2 Q9HC29 1/20 0.60
RAB9A P51151 8/20 0.59
NPC1 O15118 7/20 0.59
TRPM4 Q8TD43 2/20 0.57
HTT P42858 2/20 0.55
KCNH2 Q12809 1/20 0.55
SUCNR1 Q9BXA5 1/20 0.53
MAPT P10636 2/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
POLB P06746 2/20 0.53
G6PD P11413 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
NFKB1 P19838 1/20 0.53
NFKB2 Q00653 1/20 0.53
RELA Q04206 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4097178 0.87 KMT2A (0.60) MEN1KMT2AALDH1A1CTDSP1NOD2
SCHEMBL4293544 0.86 MEN1 (0.79) MEN1KMT2AALDH1A1KDM4ECTDSP1
SCHEMBL4295572 0.85 RAB9A (0.63) MEN1KMT2AALDH1A1RAB9ANPC1
SCHEMBL4298332 0.85 RAB9A (0.63) MEN1KMT2AALDH1A1RAB9ANPC1
SCHEMBL4299386 0.82 RAB9A (0.59) MEN1KMT2AALDH1A1KDM4ERAB9A
SCHEMBL4304244 0.81 KMT2A (0.60) MEN1KMT2AALDH1A1RAB9ANPC1
SCHEMBL4297524 0.80 MEN1 (0.61) MEN1KMT2AALDH1A1RAB9ANPC1
SCHEMBL4298335 0.80 MEN1 (0.61) MEN1KMT2AALDH1A1RAB9ANPC1
SCHEMBL4301011 0.80 MAPT (0.56) MEN1KMT2AALDH1A1RAB9ANPC1
SCHEMBL26808978 0.80 KCNK3 (0.70) MEN1KMT2AKDM4ERAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105218-A1 CRTH2 Receptor Ligands For Therapeutic Use 7TM PHARMA A/S (DK) 2009-04-23 US disclosed
US-20090105218-A1 CRTH2 Receptor Ligands For Therapeutic Use 7TM PHARMA A/S (DK) 2009-04-23 US disclosed
US-20090105218-A1 CRTH2 Receptor Ligands For Therapeutic Use 7TM PHARMA A/S (DK) 2009-04-23 US disclosed
EP-1758571-A1 CRTH2 RECEPTOR LIGANDS FOR THERAPEUTIC USE 7TM Pharma A/S (DK) 2007-03-07 EP disclosed
WO-2005115374-A1 CRTH2 RECEPTOR LIGANDS FOR THERAPEUTIC USE 7TM PHARMA A/S (DK) 2005-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105218-A1 CRTH2 Receptor Ligands For Therapeutic Use NR1H2, NR1H3, HRH2 MEN1 2859/4885KMT2A 2570/4885ALDH1A1 787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.